# NRX101 Glx Biomarker Validation Study

> **NCT03402152** · PHASE2,PHASE3 · COMPLETED · sponsor: **NeuroRx, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Bipolar Depression
- Suicidal Ideation

## Interventions

- **DRUG:** NRX-101
- **DRUG:** Lurasidone HCl
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03402152
- **Lead sponsor:** NeuroRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402152, "NRX101 Glx Biomarker Validation Study". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03402152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*